| | |
Page
|
| |||
| | | | S-ii | | | |
| | | | S-1 | | | |
| | | | S-7 | | | |
| | | | S-8 | | | |
| | | | S-9 | | | |
| | | | S-12 | | | |
Dilution | | | | | S-13 | | |
Capitalization | | | | | S-14 | | |
| | | | S-15 | | | |
Underwriting | | | | | S-19 | | |
| | | | S-24 | | | |
| | | | S-24 | | | |
| | | | S-25 | | | |
Experts | | | | | S-25 | | |
PROSPECTUS
|
| ||||||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 11 | | |
| | |
For the Three Months Ended
|
| |
For the
Year Ended 2018 |
| ||||||||||||||||||||||||
| | |
March 31,
2018 |
| |
June 30,
2018 |
| |
September 30,
2018 |
| |
December 31,
2018 |
| ||||||||||||||||||
Total Net Revenue
|
| | | $ | 6,876 | | | | | $ | 7,573 | | | | | $ | 8,131 | | | | | $ | 9,337 | | | | | $ | 31,917 | | |
Net Income
|
| | | $ | 1,921 | | | | | $ | 2,418 | | | | | $ | 2,591 | | | | | $ | 2,622 | | | | | $ | 9,552 | | |
Adjusted EBITDA
|
| | | $ | 2,043 | | | | | $ | 2,810 | | | | | $ | 2,955 | | | | | $ | 3,120 | | | |
| | |
For the Three Months Ended
|
| |
For the
Year Ended 2019 |
| |
For the
Three Months Ended March 31, 2020 |
| |||||||||||||||||||||||||||
| | |
March 31,
2019 |
| |
June 30,
2019 |
| |
September 30,
2019 |
| |
December 31,
2019 |
| ||||||||||||||||||||||||
Total Net Revenue
|
| | | $ | 9,196 | | | | | $ | 10,297 | | | | | $ | 11,817 | | | | | $ | 14,162 | | | | | $ | 45,472 | | | | | $ | 15,228 | | |
Net Income
|
| | | $ | 2,350 | | | | | $ | 2,162 | | | | | $ | 2,033 | | | | | $ | 2,947 | | | | | $ | 9,492 | | | | | $ | 2,937 | | |
Adjusted EBITDA
|
| | | $ | 2,461 | | | | | $ | 2,818 | | | | | $ | 2,805 | | | | | $ | 4,053 | | | | | | | | | | | $ | 3,023 | | |
| | |
For the Three Months Ended
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of GAAP
to Non-GAAP Measure (in thousands) |
| |
March 31,
2017 |
| |
June 30,
2017 |
| |
September 30,
2017 |
| |
December 31,
2017 |
| |
March 31,
2018 |
| |
June 30,
2018 |
| |
September 30,
2018 |
| |
December 31,
2018 |
| |
March 31,
2019 |
| |
June 30,
2019 |
| |
September 30,
2019 |
| |
December 31,
2019 |
| |
March 31,
2020 |
| |||||||||||||||||||||||||||||||||||||||
Adjusted EBITDA: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net income
|
| | | $ | 353 | | | | | $ | 1,504 | | | | | $ | 2,200 | | | | | $ | 3,308 | | | | | $ | 1,921 | | | | | $ | 2,418 | | | | | $ | 2,591 | | | | | $ | 2,622 | | | | | $ | 2,350 | | | | | $ | 2,162 | | | | | $ | 2,033 | | | | | $ | 2,947 | | | | | $ | 2,937 | | |
Depreciation and Amortization*
|
| | | | 64 | | | | | | 41 | | | | | | 111 | | | | | | 37 | | | | | | 25 | | | | | | 42 | | | | | | 59 | | | | | | 62 | | | | | | 66 | | | | | | 76 | | | | | | 50 | | | | | | 60 | | | | | | 68 | | |
Stock-based compensation expense
|
| | | | 24 | | | | | | 13 | | | | | | 9 | | | | | | 249 | | | | | | 63 | | | | | | 53 | | | | | | 76 | | | | | | 178 | | | | | | 139 | | | | | | 158 | | | | | | 259 | | | | | | 264 | | | | | | 497 | | |
Interest expense and
other (benefit), net |
| | | | 121 | | | | | | 394 | | | | | | 691 | | | | | | 244 | | | | | | 115 | | | | | | 37 | | | | | | 1 | | | | | | 0 | | | | | | (880) | | | | | | 0 | | | | | | 0 | | | | | | 4 | | | | | | 4 | | |
Income tax expense (benefit)
|
| | | | 9 | | | | | | 36 | | | | | | 44 | | | | | | 40 | | | | | | (81) | | | | | | 260 | | | | | | 228 | | | | | | 258 | | | | | | 786 | | | | | | 422 | | | | | | 463 | | | | | | 778 | | | | | | (483) | | |
Adjusted EBITDA
|
| | | $ | 571 | | | | | $ | 1,988 | | | | | $ | 3,055 | | | | | $ | 3,878 | | | | | $ | 2,043 | | | | | $ | 2,810 | | | | | $ | 2,955 | | | | | $ | 3,120 | | | | | $ | 2,461 | | | | | $ | 2,818 | | | | | $ | 2,805 | | | | | $ | 4,053 | | | | | $ | 3,023 | | |
|
| | |
For the
Three Months Ended June 30, 2020 |
| |||
20% Effective Tax Rate | | | | | | | |
Adjusted EBITDA: | | | | | | | |
Net income
|
| | | $ | 3,291 | | |
Depreciation and Amortization*
|
| | | | 97 | | |
Stock-based compensation expense
|
| | | | 579 | | |
Interest expense and other, net
|
| | | | 5 | | |
Income tax expense
|
| | | | 928 | | |
Adjusted EBITDA
|
| | | $ | 4,900 | | |
|
| | |
For the
Three Months Ended June 30, 2020 |
| |||
10% Effective Tax Rate | | | | | | | |
Adjusted EBITDA: | | | | | | | |
Net income
|
| | | $ | 3,347 | | |
Depreciation and Amortization*
|
| | | | 97 | | |
Stock-based compensation expense
|
| | | | 579 | | |
Interest expense and other, net
|
| | | | 5 | | |
Income tax expense
|
| | | | 372 | | |
Adjusted EBITDA
|
| | | $ | 4,400 | | |
|
Public offering price per share
|
| | | | | | | | | $ | | | |
|
Net tangible book value per share as of March 31, 2020
|
| | | $ | 0.70 | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering and the Concurrent Offering
|
| | | $ | | | | | | | | | |
|
As adjusted net tangible book value per share after giving effect to this offering and the Concurrent Offering
|
| | | | | | | | | $ | | | |
|
Dilution in net tangible book value per share to new investors
|
| | | | | | | | | $ | | | |
| | |
As of March 31, 2020
(Unaudited) |
| |||||||||
(amounts in thousands, except per share information)
|
| |
Actual
|
| |
As Adjusted
(Unaudited) |
| ||||||
Cash and Cash Equivalents
|
| | |
$
|
14,585
|
| | | |
$
|
|
| |
Stockholders (deficit) equity: | | | | | | | | | | | | | |
Common Stock, $0.001 par value per share, 100,000,000 shares authorized; 33,177,582 shares issued and outstanding (actual); shares issued and outstanding (as adjusted)
|
| | |
$
|
34
|
| | | |
$
|
|
| |
Additional Paid-in Capital
|
| | |
$
|
9,916
|
| | | |
$
|
|
| |
Treasury Stock
|
| | |
$
|
(3,846)
|
| | | |
$
|
|
| |
Retained Earnings
|
| | |
$
|
17,293
|
| | | |
$
|
|
| |
Total Stockholders’ Equity
|
| | |
$
|
23,397
|
| | | |
$
|
|
| |
Total Capitalization
|
| | |
$
|
23,397
|
| | | |
$
|
|
| |
Underwriter
|
| |
Number of Shares
|
| |||
Piper Sandler & Co.
|
| | | | | | |
Total
|
| | | | | | |
| | |
Total
|
| |||||||||||||||
| | |
Per Share
|
| |
Without Option
|
| |
With Option
|
| |||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | |||
Underwriting discounts and commissions
|
| | | $ | | | | | $ | | | | | $ | | | |||
Proceeds, before expenses, to Zynex, Inc.
|
| | | $ | | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 11 | | |
Product Name
|
| |
Description
|
|
Zynex Medical Products | | | | |
NexWave | | | Dual Channel, multi-modality IFC, TENS, NMES Device | |
NeuroMove | | | Electromyography (EMG) triggered Electrical Stimulation Device | |
InWave | | | Electrical stimulation for treatment of female urinary incontinence | |
TENSWave | | | Dual Channel TENS Device | |
Private Labeled Supplies | | | | |
Electrodes | | | Supplies, re-usable for delivery of electrical current to the body | |
Batteries | | | Supplies, for use in electrotherapy products | |
Distributed Complementary Products | | | | |
Comfortrac | | | Cervical traction | |
JetStream | | | Hot/Cold therapy | |
LSO Back Braces | | | Lumbar support | |
Zynex Monitoring Solutions Products | | | | |
Non-Invasive Blood Volume Monitor | | | Blood Volume Monitor | |
8MY[7O-